Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070138 | 0.90 | HPGDS (0.64) | HPGDSHTR7USP30NPC1ALDH1A1 | |
| SCHEMBL1365112 | 0.87 | MAP4K4 (0.53) | HPGDSHTR7USP30DRD2DRD4 | |
| SCHEMBL1366021 | 0.86 | DRD2 (0.52) | HPGDSHTR7USP30DRD2DRD4 | |
| SCHEMBL348209 | 0.81 | HPGDS (0.56) | HPGDSHTR7USP2DRD2DRD4 | |
| SCHEMBL1366139 | 0.81 | HPGDS (0.51) | HPGDSHTR7DRD2DRD4KDM5A | |
| SCHEMBL1365756 | 0.81 | HPGDS (0.55) | HPGDSHTR7DRD2DRD4GABRA5 | |
| SCHEMBL1367638 | 0.80 | USP30 (0.53) | HPGDSUSP30GABRA5 | |
| SCHEMBL1368210 | 0.80 | HPGDS (0.55) | HPGDSHTR7DRD2DRD4GABRA5 | |
| SCHEMBL1365108 | 0.80 | MAP4K4 (0.50) | HPGDSHTR7DRD2DRD4GABRA5 | |
| SCHEMBL1366974 | 0.79 | HPGDS (0.54) | HPGDSHTR7ALDH1A1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750749-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2017-09-05 | — | — | US | claimed |
| US-20160199386-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2016-07-14 | — | — | US | claimed |
| US-20120015001-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2012-01-19 | — | — | US | claimed |
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | claimed |
| EP-2132196-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | Pfizer Products Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | claimed |
| WO-2008104869-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | claimed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | claimed |
| US-9750749-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160199386-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2016-07-14 | — | — | US | disclosed |
| US-9320723-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2016-04-26 | — | — | US | disclosed |
| US-20120015001-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2012-01-19 | — | — | US | disclosed |
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2008104869-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104869-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885HTR7 658/4885USP30 4116/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885HTR7 658/4885USP30 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.